Eli Lilly and Novo Nordisk have agreed to sell their weight loss drugs, Wegovy and Zepbound, through the new TrumpRx ...

Trump announced popular weight loss treatments would be offered directly on a new “TrumpRx.gov” website at lower prices.

Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare ...

After writing dozens of GLP-1 articles over the past year, one issue that consistently comes up is the affordability of ...

In summary, under the Trump plan, the U.S. health system continues to fail Americans — by not viewing obesity as a disease, ...

TrumpRx will offer Novo Nordisk's Ozempic and Wegovy through TrumpRx for $350 and Eli Lilly and Company's Zepbound and orforglipron, if approved by the FDA, for $346.

By moving early, Novo Nordisk has got in with its price cut ahead of Lilly, whose deal involved dual GLP-1/CIP agonist ...

Orforglipron is Lilly’s oral GLP-1 in phase 3 development as a treatment for diabetes and obesity. The FDA is expected to approve the drug in March 2026. Lilly’s November news release states that the ...

Certain GLP-1 weight loss medications will be available for as little as $149 per month, a sharp drop from the current ...

That said, GLP-1 medications for weight loss are not for everyone, and they can cause unpleasant, even serious, side effects, ...

The Danish drugmaker said it's cutting the price of Wegovy and Ozempic from $499 to $349 per month for some customers who buy ...